| Business Summary | | InterMune,
Inc.,
formerly
known
as
InterMune
Pharmaceuticals,
Inc.,
develops
and
commercializes
products
for
the
treatment
of
serious
pulmonary
and
infectious
diseases
and
congenital
disorders.
The
Company
has
the
exclusive
license
rights
in
the
United
States
to
ActImmune
for
a
range
of
diseases,
including
chronic
granulomatous
disease,
a
life-threatening
congenital
disorder
of
the
immune
system;
osteopetrosis,
a
life-threatening
congenital
disorder
causing
an
overgrowth
of
bony
structures;
idiopathic
pulmonary
fibrosis,
a
life-threatening
lung
condition;
infections
caused
by
a
type
of
bacteria
known
as
mycobacteria
(mycobacterial
infections),
such
as
tuberculosis;
infections
caused
by
various
fungi
that
attack
patients
with
weakened
immune
systems
(systemic
fungal
infections),
such
as
cryptococcal
meningitis
and
pneumonia;
and
cystic
fibrosis,
a
congenital
disorder
that
leads
to
chronic
pulmonary
infections
in
children. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | InterMune
develops
and
commercializes
innovative
products
for
the
treatment
of
serious
pulmonary
and
infectious
diseases
and
congenital
disorders.
The
Co.
has
the
exclusive
sublicense
rights
in
the
United
States
to
ACTIMMUNE.
For
the
six
months
ended
6/01,
revenues
totalled
$13.6
million,
up
from
$3.1
million.
Net
loss
applicable
to
Common
fell
29%
to
$28.8
million.
Results
reflect
increased
sales
of
ACTIMMUNE,
and
the
absence
of
preferred
dividend
obligations. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| W. Scott Harkonen, M.D., 49 Chairman,
Pres, CEO | $306K | Timothy Lynch, 31 CFO,
VP-Bus. Devel. | 165K | James Pennington, M.D., 58 Exec.
VP of Medical and Scientific Affairs | -- | Stephen Rosenfield, 51 Sr.
VP- Legal Affairs, Gen. Counsel | 221K | Peter Van Vlasselaer, Ph.D., 42 Sr.
VP of Technical Operations | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|